Events

ESMO 2021: NORSE Study

By ONA Editor September 23, 2021 No Comments

Highlights on erdafitinib in advanced urothelial cancer with FGFRa alterations: The NORSE study

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

About Author

Related Posts

ASCO 2023: Targeted therapy achieves responses across multiple cancer types with FGFR alterations

First mutation-targeted bladder cancer drug may be under-used

ASCO 2020: Immunotherapy following chemotherapy offers extended survival to patients with advanced urothelial cancer

Leave A Reply Cancel Reply